

Abstract

The present invention relates to pharmaceutical compositions comprising a new, therapeutically effective dose of an isolated interferon-beta (IFN- β) mutein for treatment of multiple sclerosis (MS) and methods of treating MS using such pharmaceutical compositions.

- 5 More particularly, the pharmaceutical compositions of the present invention comprise a new, therapeutically effective dose of an isolated IFN- β mutein.